Key result
Chardack-Greatbatch pacemaker implantation is linked to ~89% symptom freedom in heart block patients.
Why the study?
The Chardack-Greatbatch implantable pacemaker was evaluated for managing congenital and acquired heart block with limited prior data on its use and outcomes.
Does the Chardack-Greatbatch implantable pacemaker improve symptoms and survival in patients with congenital and acquired heart block?
Observational (n=38)
Does the Chardack-Greatbatch implantable pacemaker improve symptoms and survival in patients with congenital and acquired heart block?
The Chardack-Greatbatch implantable pacemaker effectively manages symptoms in patients with congenital and acquired heart block, though early device failures pose a mortality risk.
May support symptom relief in heart block; leaves open randomized confirmation of long-term benefit and safety.
The Chardack-Greatbatch implantable pacemaker has proved a worthwhile device for the management of both congenital and acquired heart block. The procedure used for implantation in 38 patients is described. The most frequent indication for use of the pacemaker is syncope due to heart block. Progressive cardiac enlargement was also an indication for pacemaker implantation in two of four children with congenital heart block. The pacemaker has also been useful in the management of surgically induced heart block and coexisting heart block that accompanies intracardiac lesions, such as aortic stenosis, which require open-heart surgery. Pacemaker failure due to electrode breakage occurred in two patients. In both instances, a replacement unit was successfully used. Three of the 38 patients have subsequently died from causes unrelated to pacemaking while one death resulted from pacemaker failure 12 months after implantation. The remaining 34 patients have remained free from cardiac symptoms during observation periods of 2 to 24 months.
No takes yet. Share an insight, caveat, or question.
Taber et al. (1964) conducted an observational in Congenital and acquired heart block (n=38). Chardack-Greatbatch implantable pacemaker was evaluated. Implantation of the Chardack-Greatbatch pacemaker in 38 patients with heart block resulted in 34 patients remaining free from cardiac symptoms over 2 to 24 months of observation.